ASCO 2013: bevacizumab and glioblastoma – a marriage dissolution?. (September 2014)

• Record Type: Journal Article
• Authors: Addeo, Raffaele; Perri, Francesco; Parlato, Ciro; Della Vittoria, Giuseppina
• Is Part Of: Current medical research and opinion. Volume 30:Number 9(2014:Sep.)
• Page Start: 1871
• Page End: 1873
• Publication Date: 2014-09
• Subjects: Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1185/03007995.2014.921145
• Languages: English
• ISSNs: 0300-7995

Abstract

<abstract> <title>Abstract</title> <p>The prognosis of patients affected by glioblastoma (GBM) is grim albeit the integrated therapeutic approaches now available. Standard surgery followed by chemoradiation median overall survival (OS) reaches 15 months in clinical trials. Despite primary treatment, recurrence is the rule in patients with GBM and for them OS ranges from 6 to 9 months. In recent years, the therapeutic scenario has been profoundly changed in view of the promising results obtained by bevacizumab (Avastin<xref ref-type="fn" rid="fn1">*</xref> ), the most promising anti-angiogenesis agent, in two clinical trials. The results of both trials were presented at the last ASCO meeting in Chicago. Progression free survival was significantly improved with an acceptable safety and tolerability profile but surprisingly quality of life was preserved only in the AVAGlio trial. However, both studies showed that overall survival was not improved adding bevacizumab to temozolomide and radiotherapy.</p> </abstract>